Longenesis is Leading Research into Respiratory Tract Infections in Children
Longenesis Partners with Ewopharma
Longenesis, a leading digital health startup in the Baltics, has partnered with Swiss pharmaceutical company Ewopharma to conduct a novel clinical trial into respiratory tract infections in children.
Acute respiratory infections, otherwise known as ARIs, are serious medical conditions that are one of the leading causes of hospitalization among children. Globally, the number of acute respiratory infections has been increasing significantly over the past few years, reaching a total of more than 17 billion in 2019. (1)
In order to understand the complex risk factors behind ARIs in children and advance development of effective treatments further clinical research is necessary. As such, Longenesis is pleased to lead the latest innovative research study that will follow patients from Central and Eastern European countries receiving an antiviral drug targeting respiratory tract infections.
Why Longenesis?
The role of Longenesis in this observational, multicentre study lies in the provision of a digital engagement tool, e-consent, patient diary and reminder functionality. More specifically, the Longenesis Engage platform will enable digital consent management and streamline data collection for both investigators and participants' parents taking part in the study.
The Longenesis Engage platform will facilitate the safe and convenient management of informed consent for both the child and the legal guardian, which is essential for the execution of the clinical trial. Certified by the highest standard of data privacy and security (ISO/IEC 27001) Longenesis is committed to upholding the highest ethical standards and maintaining the privacy and protection of participants' information.
As stated by a representative from Ewopharma: "We're excited to announce the initiation of our real-world data study on pediatric recurrent respiratory infections, facilitated by our collaboration with Longenesis, a pioneering digital health company. Their advanced digital tools for participant and caregiver engagement, along with streamlined consent management, have significantly expedited our study process. With real-time data management and feedback, investigators can operate more efficiently, ensuring participant-centricity and upholding the highest standards of data security as the study progresses."
The results of the study are expected to be published in February of 2028.
Longenesis, a leading digital health startup in the Baltics, has partnered with Swiss pharmaceutical company Ewopharma to conduct a novel clinical trial into respiratory tract infections in children.
Acute respiratory infections, otherwise known as ARIs, are serious medical conditions that are one of the leading causes of hospitalization among children. Globally, the number of acute respiratory infections has been increasing significantly over the past few years, reaching a total of more than 17 billion in 2019. (1)
In order to understand the complex risk factors behind ARIs in children and advance development of effective treatments further clinical research is necessary. As such, Longenesis is pleased to lead the latest innovative research study that will follow patients from Central and Eastern European countries receiving an antiviral drug targeting respiratory tract infections.
Why Longenesis?
The role of Longenesis in this observational, multicentre study lies in the provision of a digital engagement tool, e-consent, patient diary and reminder functionality. More specifically, the Longenesis Engage platform will enable digital consent management and streamline data collection for both investigators and participants' parents taking part in the study.
The Longenesis Engage platform will facilitate the safe and convenient management of informed consent for both the child and the legal guardian, which is essential for the execution of the clinical trial. Certified by the highest standard of data privacy and security (ISO/IEC 27001) Longenesis is committed to upholding the highest ethical standards and maintaining the privacy and protection of participants' information.
As stated by a representative from Ewopharma: "We're excited to announce the initiation of our real-world data study on pediatric recurrent respiratory infections, facilitated by our collaboration with Longenesis, a pioneering digital health company. Their advanced digital tools for participant and caregiver engagement, along with streamlined consent management, have significantly expedited our study process. With real-time data management and feedback, investigators can operate more efficiently, ensuring participant-centricity and upholding the highest standards of data security as the study progresses."
The results of the study are expected to be published in February of 2028.
(1) Zimmerman, R.K., Balasubramani, G.K., D'Agostino, H.E., Clarke, L., Yassin, M., Middleton, D.B., Silveira, F.P., Wheeler, N.D., Landis, J., Peterson, A. and Suyama, J., 2022. Population‐based hospitalization burden estimates for respiratory viruses, 2015–2019. Influenza and Other Respiratory Viruses, 16(6), pp.1133-1140.